IDH2 and central nervous system cancer: The stratification of gliomas based on the presence or absence of mutations in IDH1 or IDH2 has represented a major advancement in the understanding of glioma biology and has improved diagnostic and prognostic accuracy, to the extent that this criterion alone is sufficient to discriminate between astrocytomas and glioblastomas.